I last covered BridgeBio Pharma (NASDAQ: BBIO ) in April, just before earnings. Since then, earnings were a huge beat, but the stock has been roughly flat since then, underperforming the major indexes. Still, despite the underwhelming price action, new dataLike millions of other investors, I got Robinhood and started trading during the pandemic. Unlike most of those investors, I carefully studied hundreds of earnings reports for clues to future performance, and I was able to identify many future winners, su ...